Submission of Matters to a Vote of Security Holders Form 8 K

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a)            Leap Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting") on July 2, 2024.

(b)            The final voting results on each of the matters submitted to a vote of stockholders at the Annual Meeting are set forth below.

(1) The following director nominees were elected to serve as Class I directors until the Company's 2027 annual meeting of stockholders and until their successors are duly elected and qualified.

Nominee		Votes For		Votes Withheld		Broker Non-Votes
James Cavanaugh		16,740,789		1,392,072		7,871,104
Douglas E. Onsi		17,084,768		1,048,093		7,871,104
Christian Richard		17,809,064		323,797		7,871,104
Richard Schilsky		16,813,357		1,319,504		7,871,104

(2) The Company's stockholders approved, on an advisory basis, the executive compensation of the Company's named executive officers.

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes
16,820,682		1,272,059		40,120		7,871,104

(3) The Amendment to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan was approved.

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes
16,572,103		1,480,150		80,608		7,871,104

(4) The appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.

Votes For		Votes Against		Votes Abstaining
25,894,496		71,613		37,856

Public link

Please use the above public link if you want to share this noodl on another website.